Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. METHODS: In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concomitant topical agents. The primary end point was the mean percent change in the visual-analogue scale (VAS) score for pruritus (range, 0 to 100, with higher scores indicating worse pruritus) from baseline to week 16. Secondary end points included the time course of change in the VAS score for pruritus up to week 4, the change in the Eczema Area and Severity Index (EASI) score (range, 0 to 72, with higher scores indicating greater severity), a score of 4 or less on the Dermatology Life Quality Index (DLQI; range, 0 to 30, with higher scores indicating a greater effect on daily life), a score of 7 or less on the Insomnia Severity Index (ISI; range, 0 to 28, with higher scores indicating greater severity), and safety. RESULTS: A total of 143 patients were randomly assigned to receive nemolizumab and 72 to receive placebo. The median VAS score for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was -42.8% in the nemolizumab group and -21.4% in the placebo group (difference, -21.5 percentage points; 95% confidence interval, -30.2 to -12.7; P<0.001). The mean percent change in the EASI score was -45.9% with nemolizumab and -33.2% with placebo. The percentage of patients with a DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group; the percentage of patients with an ISI score of 7 or less was 55% and 21%, respectively. The incidence of injection-related reactions was 8% with nemolizumab and 3% with placebo. CONCLUSIONS: In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The EASI score showed a moderate improvement of 46% with nemolizumab versus 33% in the placebo group192.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
In the citing paper
“The overall efficacy in pruritus in combination with TCSs was further confirmed in a phase III study over 16 weeks with a decrease of 43% versus 21% in the placebo group as measured by the visual analogue scale score.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011) · Sleep · doi:10.1093/sleep/34.5.601 · Cited by 4,620
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Research works printed but not linked: 1
- Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019;1:CD012167-CD012167.30666626
Cited by
Items 101–200 of 369
Rothenberg‐Lausell, C., Bar, J., Dahabreh, D., Renert‐Yuval, Y., DUCA, E. D., & Guttman‐Yassky, E. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.04.009 · Cited by 27
Miyano, T., Irvine, A. D., & Tanaka, R. J. (2021) · Allergy · doi:10.1111/all.14870 · Cited by 30
Strategies for choosing a biologic for your patient with allergy or asthma
Saco, T. V., Ugalde, I. C., Cardet, J. C., & Casale, T. B. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.09.009 · Cited by 26
Mastorino, L., Rosset, F., Gelato, F., Ortoncelli, M., Cavaliere, G., Quaglino, P., & Ribero, S. (2022) · Pharmaceuticals · doi:10.3390/ph15070883 · Cited by 25
Does, A. V., Ju, T., Mohsin, N., Chopra, D., & Yosipovitch, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108355 · Cited by 28
Caffarelli, C., Giannetti, A., Giannì, G., & Ricci, G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1214963 · Cited by 27
Igarashi, A., Katsunuma, T., Nagano, Y., & Komazaki, H. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae458 · Cited by 25
Self-citationPala, V., Rosset, F., Mastorino, L., Sciamarrelli, N., Boskovic, S., Borriello, S., Bongiovanni, E., Crespi, O., Ribero, S., & Quaglino, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110720 · Cited by 25
Cutaneous neuroimmune crosstalk in pruritus
Agelopoulos, K., Pereira, M. P., Wiegmann, H., & Ständer, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.005 · Cited by 30
The Dawn of a New Era in Atopic Dermatitis Treatment
Yamamura, K., & Nakahara, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206145 · Cited by 27
Roy, Y. R. L., Ficheux, A., Misery, L., & Brenaut, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1079323 · Cited by 28
Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles
Chigbu, D. I., Karbach, N. J., Abu, S. L., & Hehar, N. K. (2024) · Life · doi:10.3390/life14030350 · Cited by 36
Quirce, S., Cosío, B. G., España, A., Blanco, R., Mullol, J., Santander, C., & del Pozo, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192284 · Cited by 27
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Waligóra-Dziwak, K., Dańczak‐Pazdrowska, A., & Jenerowicz, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144001 · Cited by 23
Cutaneous Adverse Events Following Nemolizumab Administration: A Review
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093026 · Cited by 23
Gan, C., Mahil, S. K., Pink, A., & Rodrigues, M. A. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad162 · Cited by 23
Macrophages in inflammatory skin diseases and skin tumors
Liu, S., Zhang, J., & Zuo, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430825 · Cited by 23
Li, D., Han, Y., Zhou, J., Yang, H., Chen, J., Tey, H. L., & Tan, T. T. Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1645095 · Cited by 22
Chen, Q., Cui, L., Hu, Y., Chen, Z., Gao, Y., & Shi, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22014 · Cited by 22
Fototerapia en el prurigo nodular. Experiencia propia y revisión de la literatura
Arrieta, A., Jaka, A., del Alcázar, E., Blanco, M., & Carrascosa, J. M. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2020.11.007 · Cited by 21
Current Clinical Options for the Management of Itch in Atopic Dermatitis
Lipman, Z. M., Labib, A., & Yosipovitch, G. (2021) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s289716 · Cited by 24
A new era has begun: Treatment of atopic dermatitis with biologics
Stölzl, D., Weidinger, S., & Drerup, K. A. (2021) · Allergologie select · doi:10.5414/alx02259e · Cited by 22
A case of bullous pemphigoid following administration of anti‐IL ‐31 receptor A antibody
Masuyuki, R., Sato, E., & Imafuku, S. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17171 · Cited by 19
Biologic and Small Molecule Therapy in Atopic Dermatitis
Shergill, M., Bajwa, B., Yilmaz, O., Tailor, K., Bouadi, N., & Mukovozov, I. (2024) · Biomedicines · doi:10.3390/biomedicines12081841 · Cited by 20
Maglie, R., Ugolini, F., Logu, F. D., Nassini, R., Simi, S., Nardiello, P., Pasqualini, E., Baroni, G., BIANCO, E. D., Massi, D., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.07.007 · Cited by 19
Kim, H.-O. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01421-2 · Cited by 20
IL-31/33 Axis in Atopic Dermatitis
Łacwik, J., Kraik, K., Laska, J., Tota, M., Sędek, Ł., & Gomułka, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010162 · Cited by 20
Qi, H.-J., & Li, L. (2021) · BioMed Research International · doi:10.1155/2021/5528372 · Cited by 19
A New Era with the Development of Cytokine-Based Therapy for Pruritus
Shibuya, R., Takimoto‐Ito, R., Kambe, N., & Kabashima, K. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.023 · Cited by 20
Self-citationCostanzo, A., on behalf of Italian AD Study Group, AMERIO, P., ASERO, R., Chiricozzi, A., CORAZZA, M., CRISTAUDO, A., Cusano, F., Ferrucci, S. M., Nettis, E., et al. (2021) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.21.07129-2 · Cited by 20
Characterization of the effects on pruritus by novel treatments for atopic dermatitis
Bonnekoh, H., Butze, M., & Metz, M. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14678 · Cited by 20
Jeong, N., Lee, S., Choi, Y., Song, K., & Kim, S. (2022) · Inflammation · doi:10.1007/s10753-022-01652-x · Cited by 17
Kunimura, K., & Fukui, Y. (2021) · International Immunology · doi:10.1093/intimm/dxab065 · Cited by 19
Novel systemic treatments in atopic dermatitis: Are there sex differences?
Tuttle, K. L., Forman, J., & Beck, L. A. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.10.002 · Cited by 17
The Epidermis: Redox Governor of Health and Diseases
Ishitsuka, Y., & Roop, D. R. (2021) · Antioxidants · doi:10.3390/antiox11010047 · Cited by 19
Kataoka, Y. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2024.1473902 · Cited by 18
Advancing Therapeutic Strategies in Atopic Dermatitis: Emerging Targets and Personalized Approaches
Lo, Y., Cheng, T.-T., Huang, C., Cheng, Y., & Chyuan, I. (2025) · Biomolecules · doi:10.3390/biom15060838 · Cited by 20
Study of the specificity of gut microbiota in adult patients with delayed-onset of atopic dermatitis
Liu, T., Yang, C. H., He, J., Wang, Y., Hu, T., & Zhang, X. (2022) · Allergologia et Immunopathologia · doi:10.15586/aei.v50i6.705 · Cited by 17
He, S., Xie, F., Su, W., Luo, H.-B., Chen, D., Cai, J., & Hong, X. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14030150 · Cited by 15
A critical evaluation of nemolizumab for prurigo nodularis
Brooks, S. G., & Yosipovitch, G. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2306225 · Cited by 15
Sensory neuroimmune interactions at the barrier
Wang, Z., Song, K., Kim, B., & Manion, J. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.10.001 · Cited by 17
Advances in Drug Delivery Systems for Atopic Dermatitis Treatment
Yang, J., Jing, L., Li, Y., Deng, D., & Miao, Y. (2024) · ChemBioChem · doi:10.1002/cbic.202400968 · Cited by 16
IL-31, itch and hematological malignancies
Salvo, E. D., Allegra, A., Casciaro, M., & Gangemi, S. (2021) · Clinical and Molecular Allergy · doi:10.1186/s12948-021-00148-7 · Cited by 16
Evaluation, management and future perspectives of anal pruritus: a narrative review
Jakubauskas, M., & Dulskas, A. (2023) · European journal of medical research · doi:10.1186/s40001-023-01018-5 · Cited by 15
Honda, T., Kabashima, K., & Kunisawa, J. (2023) · Immunological Reviews · doi:10.1111/imr.13193 · Cited by 16
Self-citationThe Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy
Zhang, Z., Chang, C., Xiao, L., Su, H., Lyu, Y., Zhao, J., Chen, J., Gou, K., Zhou, J., Wang, C., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s578036 · Cited by 15
Kim, J. H., & Samra, M. S. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.00346 · Cited by 14
Mostafa, N., Phan, K. H., Lai, B., & Smith, S. D. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1970529 · Cited by 14
Kabashima, K., Matsumura, T., Komazaki, H., Kawashima, M., & The Nemolizumab-JP01 Study Group (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00901-7 · Cited by 14
Self-citationFuruhashi, T., Oda, T., Torii, K., Nishida, E., & Morita, A. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15638 · Cited by 14
Innate Immune Regulation of Dermatitis
Abreu, D., & Kim, B. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.04.011 · Cited by 15
Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis
Miyano, T., Irvine, A. D., & Tanaka, R. J. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100110 · Cited by 15
Silverberg, J. I., Mustapa, M. N., Reid, F., Lei, A., Smith, R., Moate, R., Kelly, A., Chen, R., Gavala, M. L., Jiménez, E., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20388 · Cited by 14
Epigenetics of Cutaneous Sarcoma
Mashima, E., & Sawada, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010422 · Cited by 13
The suitability of treating atopic dermatitis with Janus kinase inhibitors
Narla, S., & Silverberg, J. I. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2060822 · Cited by 13
Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis
Koumaki, D., Gregoriou, S., Evangelou, G., & Krasagakis, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062091 · Cited by 14
Hua, C., Liang, Q., Chen, S., Zhu, J., Tang, Y., Chen, X., Song, Y., van der Veen, S., & Cheng, H. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03365-w · Cited by 13
English version of Japanese guidance for biologics in treating atopic dermatitis
Saeki, H., Akiyama, M., Abe, M., Igarashi, A., Imafuku, S., Ohya, Y., Katoh, N., Kameda, H., Kabashima, K., Tsunemi, Y., et al. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16932 · Cited by 13
Self-citationAtopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches
Lee, H. W., Ju, Y. J., Choi, S., Rhew, K., Sevilleno, S. S., & Choi, M. S. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.081 · Cited by 14
Electrically Evoked Itch in Human Subjects
Solinski, H. J., & Rukwied, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.627617 · Cited by 13
Emerging Nanotechnology Backed Formulations for the Management of Atopic Dermatitis
Mahato, R. K., Singh, M., Pathak, H., Gogoi, N. R., Kharbithai, R., Chowrasia, P., Bora, P. L., Sarkar, T., Jana, B. K., & Mazumder, B. (2023) · Therapeutic Delivery · doi:10.4155/tde-2023-0033 · Cited by 12
D’Auria, E., Indolfi, C., Acunzo, M., Dinardo, G., Comberiati, P., Peroni, D. G., Zuccotti, G., & del Giudice, M. M. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2452247 · Cited by 11
Yokozeki, H., Murota, H., & Matsumura, T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf045 · Cited by 11
Self-citationHonryo, A., Masuda, T., Nakamizo, S., Takafuji, T., Minami, F., Yonekura, S., Uchibayashi, M., Inoue, K., Kiyonari, H., Yamanaka, M., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.02.044 · Cited by 11
Self-citationWeidinger, S., Aoki, V., Dhar, S., Dlova, N. C., Kabashima, K., Ma, L., Flohr, C., & Irvine, A. D. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00703-z · Cited by 16
Self-citationImmunotherapy in Atopic Dermatitis
Li, W., & Man, X. (2022) · Immunotherapy · doi:10.2217/imt-2022-0054 · Cited by 12
The Future of Atopic Dermatitis Treatment
Lovell, K. K., Patel, N., Rao, S., & Strowd, L. C. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-54513-9_19 · Cited by 11
Katoh, N., Tanaka, A., Takahashi, H., Shimizu, R., Kataoka, Y., Torisu‐Itakura, H., Morisaki, Y., & Igawa, K. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2436982 · Cited by 14
Ahn, J., Grinich, E. E., Choi, Y. S., Guttman‐Yassky, E., & Simpson, E. L. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.02.003 · Cited by 11
Differential Diagnosis and Treatment of Itching in Children and Adolescents
Kang, S. Y., Um, J., Chung, B. Y., Kim, J. C., Park, C. W., & Kim, H. O. (2021) · Biomedicines · doi:10.3390/biomedicines9080919 · Cited by 11
Masuda, T., Yonekura, S., Kataoka, K., Mizoguchi, K., Hirata, M., Fujimoto, M., Nakajima, S., & Kabashima, K. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.17085 · Cited by 10
Self-citationThe role of nemolizumab in the treatment of atopic dermatitis for the adult population
Prajapati, S., Flemming, J. P., Khan, D., Han, H., How, B., Rozenberg, S. S., & Feldman, S. R. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2383554 · Cited by 10
Kawamoto, N., Murai, H., Nogami, K., Yamamoto, T., Kikkawa, T., Yasutomi, M., Yamamoto‐Hanada, K., Futamura, M., & Ohya, Y. (2025) · Allergology International · doi:10.1016/j.alit.2024.11.007 · Cited by 10
Sasaki, W., Saito, R., Suzuki, K. M., Watanabe, D., Minami‐Hori, M., Kamada, H., Amano, H., Uchiyama, A., Motegi, S., Kamura, M., et al. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17877 · Cited by 10
A new era in atopic dermatitis treatment and evolving therapeutic strategies
Honda, T. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2567133 · Cited by 11
Kabashima, K., Matsumura, T., Hayakawa, Y., Kawashima, M., & for the Nemolizumab-JP01 Study Group (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2177096 · Cited by 12
Self-citationBlockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis
Komori, T., Hisaoka, T., Kotaki, A., Iwamoto, M., Miyajima, A., Esashi, E., & Morikawa, Y. (2023) · The FASEB Journal · doi:10.1096/fj.202301529r · Cited by 11
Experimental Drugs with the Potential to Treat Atopic Eczema
Hon, K. E., Chan, V. P. Y., & Leung, A. K. C. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259299 · Cited by 10
New insight of itch mediators and proinflammatory cytokines in epidermolysis bullosa
Nguyen, H. H., Shinkuma, S., Hayashi, R., Katsumi, T., Nishiguchi, T., Natsuga, K., Fujita, Y., & Abe, R. (2022) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12230 · Cited by 9
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy
Deng, F., Qiu, Y., Zhang, X., Guo, N., Hu, J., Yang, W., Shang, W., Liu, B., & Qin, S. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbad032 · Cited by 9
The Role of Killer Ig-like Receptors in Diseases from A to Z
Agnello, L., Masucci, A., Tamburello, M., Vassallo, R., Massa, D., Giglio, R. V., Midiri, M., Gambino, C. M., & Ciaccio, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073242 · Cited by 9
Treatment of atopic dermatitis with biologics and Janus kinase inhibitors
Thyssen, J. P., & Thomsen, S. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00717-0 · Cited by 9
Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms
Wong, L., & Yen, Y.-T. (2022) · Diagnostics · doi:10.3390/diagnostics12071772 · Cited by 9
Clinical trials of antibody drugs in the treatments of atopic dermatitis
Zhou, G., Huang, Y., & Chu, M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1229539 · Cited by 9
Biological medication in atopic dermatitis
Fölster‐Holst, R., Torrelo, A., Das, K., Murrell, D. F., Patil, A. D., Rokni, G. R., Grabbe, S., Staubach, P., Sohn, A., & Goldust, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2026920 · Cited by 10
Nemolizumab for treatment of lichen amyloidosis
Nakagawa, S., Ueda‐Hayakawa, I., & Fujimoto, M. (2025) · JAAD Case Reports · doi:10.1016/j.jdcr.2025.06.010 · Cited by 8
Ko, H., Woo, Y. R., Ko, J. Y., Kim, H. O., Na, C. H., Bae, Y., Seo, Y., Shin, M. K., Ahn, J., Lew, B., et al. (2025) · Annals of Dermatology · doi:10.5021/ad.24.154 · Cited by 8
Update on management of pediatric atopic dermatitis
Jeon, Y. H., & Kim, J. H. (2021) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2021.9.2.59 · Cited by 9
Gurnani, P., Miloh, T., Chandar, J. J., Landau, D., Hajjar, F. M., & Yosipovitch, G. (2021) · Pediatric Dermatology · doi:10.1111/pde.14596 · Cited by 9
Emerging Systemic Treatment Options in Atopic Dermatitis
Salman, A., & Giménez‐Arnau, A. M. (2024) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2024.2024-5-78 · Cited by 8
Nusbaum, K. B., Fleischer, S., & Fleischer, A. B. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1986204 · Cited by 10
A translational approach to improve therapeutics in atopic dermatitis and beyond
Liu, D., Patel, D., Lau, M., Largen, J., Hu, B., He, H., & Guttman‐Yassky, E. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf049 · Cited by 7
Fukumoto, T., Tanaka, R., Tanaka, R., Hashimoto, S., Yoshioka, A., Natsuaki, S., & Kubo, A. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20039 · Cited by 7
Sato, E., Arima, H., Tsutsui, K., Shimizu, H., Ito, K., Iwata, M., & Imafuku, S. (2025) · Experimental Dermatology · doi:10.1111/exd.70120 · Cited by 7
When topical therapy of atopic dermatitis fails: a guide for the clinician
Ingrasci, G., Lipman, Z. M., & Yosipovitch, G. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.2000390 · Cited by 7
Xiong, H., Yang, J. P., Liu, T., Liu, G., Han, Y., & Dong, X. (2022) · Mediators of Inflammation · doi:10.1155/2022/6206883 · Cited by 7
Prurito en dermatología. Enfermedades y su tratamiento. Parte 2
Navarro‐Triviño, F. J. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.03.004 · Cited by 7
Wen, X., Yu, H., Zhang, L., Li, L., Wang, X., Fu, X., Sun, Z., Zhang, X., Zhu, L., Wu, X., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111777 · Cited by 7
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
David, E., Hawkins, K. A., Shokrian, N., DUCA, E. D., & Guttman‐Yassky, E. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2368192 · Cited by 7
IL‐31 and IL‐31 receptor alpha in pemphigus: Contributors to more than just itch?
Okuno, S., Hashimoto, T., Yamazaki, Y., Okuzawa, M., & Satoh, T. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16730 · Cited by 7
Metadata
- Authors
- Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M.
- Affiliations
- Kyoto University (JP)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-07-09
- Volume
- 383
- Issue
- 2
- Pages
- 141-150
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3040869725
- Cited by
- 361
- References
- 39
- Citations by year
- 2026: 37 · 2025: 68 · 2024: 57 · 2023: 67 · 2022: 51 · 2021: 73 · 2020: 7
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Maruho co., Ltd.
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, pruritus, nemolizumab, monoclonal antibodies, topical corticosteroids, topical calcineurin inhibitors, Eczema Area and Severity Index, Dermatology Life Quality Index, insomnia, Japanese patients, treatment efficacy and safety, visual analogue scale
- MeSH terms
- Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Dermatitis, Atopic, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids, Histamine Antagonists, Humans, Injections, Subcutaneous, Male, Middle Aged, Pruritus, Young Adult, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Visual Analog Scale, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.